Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Association of Hypometilating Agents + Venetoclax in the Treatment of Secondary Acute Myeloid Leukemias Evolved from Chronic Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 6711.

https://doi.org/10.1182/blood-2024-207060

Published: 2024

Journal Articles

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

Marco Cerrano, Lazzarotto Davide, Eleonora Boscaro, Erika Borlenghi, Ilaria Tanasi, Patrizia Chiusolo, Paola Minetto, Francesco Grimaldi, Michelina Dargenio, Matteo Leoncin, Silvia Trappolini, Cristina Papayannidis, Fabio Forghieri, Carmela Gurrieri, Patrizia Zappasodi, Roberta La Starza, Nicola Fracchiolla, Federica Di Biase, Maria Ilaria Del Principe, Marzia Defina, Crescenza Pasciolla, Benedetta Cambò, Federico Mosna, Daniela Pietrasanta, Sabrina Mariani, Valentina Mancini, Fabio Guolo, Federico Lussana, Elisabetta Todisco, Mario Annunziata, Valeria Calafiore, Maria Ciccone, Matteo Piccini, Matteo Emidio Dragani, Beatrice Sani, Endri Mauro, Claudia Basilico, Beatrice De Marco, Marco Antonacci, Laura Forlani, Monica Fumagalli, Fabio Trastulli, Monia Lunghi, Prassede Salutari, Sara Mastaglio, Sabina Chiaretti, Anna Candoni, Felicetto Ferrara, Giovanni Pizzolo, Robin Foà, Massimiliano Bonifacio

Blood (2024) 144 (Supplement 1): 113.

https://doi.org/10.1182/blood-2024-206854

Published: 2024

Journal Articles

Prognostic Impact of CD47 Overexpression in Patients with Acute Myeloid Leukemia

Vincenzo Sammartano, Elena Bestoso, Paola Pacelli, Adele Santoni, Anna Sicuranza, Marzia Defina, Corrado Zuanelli Brambilla, Mariachiara Cuccaro, Donatella Raspadori, Elisabetta Abruzzese, Monica Bocchia

Blood (2024) 144 (Supplement 1): 6084.

https://doi.org/10.1182/blood-2024-194696

Published: 2024

Journal Articles

Multicenter Campus ALL Study on Infectious Complications in Ph- Acute Lymphoblastic Leukemia Patients Treated in the Real Life with the Gimema LAL1913 Protocol

Blood (2023) 142 (Supplement 1): 5877.

https://doi.org/10.1182/blood-2023-182976

Published: 2023

Journal Articles

Use of Ponatinib Alone or Combined with Other Therapies in Relapsed/Refractory Ph-like Acute Lymphoblastic Leukemia. a Campus ALL Real-Life Study

Monia Lunghi, Francesca Kaiser, Deborah Cardinali, Claudia Basilico, Marzia Defina, Sara Mastaglio, Lazzarotto Davide, Prassede Salutari, Matteo Piccini, Valeria Cardinali, Antonio Pierini, Nicola Fracchiolla, Federica Di Biase, Mario Annunziata, Mariangela Di Trani, Felicetto Ferrara, Giovanni Pizzolo, Robin Foà, Sabina Chiaretti

Blood (2023) 142 (Supplement 1): 1507.

https://doi.org/10.1182/blood-2023-182091

Published: 2023

Journal Articles

Tyrosine Kinase Inhibitor (TKI) Discontinuation in Non-Allografted Ph+ Acute Lymphoblastic Leukemia Patients, a Campus ALL Real-Life Study

Matteo Dragani, Roberta Agrippino, Giovanna Rege Cambrin, Matteo Leoncin, Marco Cerrano, Prassede Salutari, Antonino Mulè, Cristina Papayannidis, Marzia Defina, Giulia Rivoli, Elisabetta Todisco, Elisabetta Abruzzese, Michele Cedrone, Nicola Fracchiolla, Fabio Guolo, Giuseppe Lanzarone, Robin Foà, Sabina Chiaretti

Blood (2023) 142 (Supplement 1): 2835.

https://doi.org/10.1182/blood-2023-187668

Published: 2023

Journal Articles

Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine

Valeria Santini, Cristina Amato, Sven De Pourcq, Roberta della Seta, Barbara Caciagli, Marco Gabriele Raddi, Angela Consagra, Luca Rigodanza, Giorgio Mattiuz, Marzia Defina, Sara Galimberti, Giacomo Maestrini, Alessandro Sanna

Blood (2023) 142 (Supplement 1): 6501.

https://doi.org/10.1182/blood-2023-190016

Published: 2023

Journal Articles

In Search of Drivers of CD34+/CD38-/CD26+ Leukemia Stem Cells Persistence in CML Patients

Paola Pacelli, Elena Bestoso, Anna Sicuranza, Elisabetta Abruzzese, Luigiana Luciano, Alessandra Iurlo, Marzia Defina, Sara Fredducci, Monica Crugnola, Valentina Giai, Federica Sorà, Sara Galimberti, Donatella Raspadori, Monica Bocchia

Blood (2022) 140 (Supplement 1): 12171–12172.

https://doi.org/10.1182/blood-2022-169085

Published: 2022

Journal Articles

ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report

Blood (2021) 138 (Supplement 1): 216.

https://doi.org/10.1182/blood-2021-150958

Published: 2021

Journal Articles

Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study

Blood (2021) 138 (Supplement 1): 3408.

https://doi.org/10.1182/blood-2021-147325

Published: 2021

Journal Articles

Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation

Monica Bocchia, Anna Sicuranza, PhD, Paola Pacelli, PhD, Patrizia Pregno, Mario Annunziata, Federica Sorà, MD, Elisabetta Abruzzese, MD, Monica Crugnola, MD, Luigiana Luciano, MD, Alessandra Iurlo, MD, Sara Galimberti, MD PhD, Anna Marina Liberati, Ilaria Ferrigno, PhD, Sara Ciofini, Marzia Defina, Luca Puccetti, Donatella Raspadori, PhD

Blood (2019) 134 (Supplement_1): 2919.

https://doi.org/10.1182/blood-2019-122814

Published: 2019

Journal Articles

Persistence of Residual Circulating CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Blood (2017) 130 (Supplement 1): 249.

https://doi.org/10.1182/blood.V130.Suppl_1.249.249

Published: 2017

Journal Articles

Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status?

Lara Aprile, Luca Puccetti, Sara Galimberti, Antonella Gozzini, Francesca Scarpini, Marzia Defina, Federica De Majo, Claudia Baratè, Anna Sicuranza, Veronica Candi, Barbara Scappini, Donatella Raspadori, Alessandro Gozzetti, Alberto Bosi, Mario Petrini, Monica Bocchia

Blood (2013) 122 (21): 1482.

https://doi.org/10.1182/blood.V122.21.1482.1482

Published: 2013

Journal Articles

Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy.

Blood (2010) 116 (21): 3413.

https://doi.org/10.1182/blood.V116.21.3413.3413

Published: 2010

Journal Articles

Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study

Blood (2010) 116 (21): 4029.

https://doi.org/10.1182/blood.V116.21.4029.4029

Published: 2010

Journal Articles

Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia

Blood (2010) 115 (14): 2755–2762.

https://doi.org/10.1182/blood-2009-07-229815

Published: 2010

Journal Articles

Long Term Follow up Analysis Following Front Line Therapy with Dexamethasone or Dexamethasone Plus Rituximab in Adults with Primary Immune Thrombocytopenia.

Blood (2009) 114 (22): 2415.

https://doi.org/10.1182/blood.V114.22.2415.2415

Published: 2009

Journal Articles

Clinical and Biological EFFECTS of 5-Azacitidine FIVE Days/Monthly Schedule IN Symptomatic LOW-RISK (IPSS: 0-1) Myelodisplastic Patient.

Blood (2009) 114 (22): 4851.

https://doi.org/10.1182/blood.V114.22.4851.4851

Published: 2009

Journal Articles

Four Drugs Combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 65 Ys: Response and Follow-up of 84 Patients.

Michela Rondoni, Michele Malagola, Stefania Paolini, Marzia Defina, Pier Paolo Piccaluga, Lara Aprile, Cristina Papayannidis, Nicoletta Testoni, Rosaria Crupi, Alessandro Gozzetti, Monica Tozzi, Giuseppe Marotta, Francesca Toraldo, Domenico Russo, Monica Bocchia, Michele Baccarani, MD, Giovanni Martinelli, Francesco Lauria, MD

Blood (2009) 114 (22): 4147.

https://doi.org/10.1182/blood.V114.22.4147.4147

Published: 2009

Journal Articles

BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.

Blood (2009) 114 (22): 648.

https://doi.org/10.1182/blood.V114.22.648.648

Published: 2009

NARROW

Association of Hypometilating Agents + Venetoclax in the Treatment of Secondary Acute Myeloid Leukemias Evolved from Chronic Myelomonocytic Leukemia

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

Prognostic Impact of CD47 Overexpression in Patients with Acute Myeloid Leukemia

Multicenter Campus ALL Study on Infectious Complications in Ph- Acute Lymphoblastic Leukemia Patients Treated in the Real Life with the Gimema LAL1913 Protocol

Use of Ponatinib Alone or Combined with Other Therapies in Relapsed/Refractory Ph-like Acute Lymphoblastic Leukemia. a Campus ALL Real-Life Study

Tyrosine Kinase Inhibitor (TKI) Discontinuation in Non-Allografted Ph+ Acute Lymphoblastic Leukemia Patients, a Campus ALL Real-Life Study

Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine

In Search of Drivers of CD34+/CD38-/CD26+ Leukemia Stem Cells Persistence in CML Patients

ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report

Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study

Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation

Persistence of Residual Circulating CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status?

Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy.

Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study

Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia

Long Term Follow up Analysis Following Front Line Therapy with Dexamethasone or Dexamethasone Plus Rituximab in Adults with Primary Immune Thrombocytopenia.

Clinical and Biological EFFECTS of 5-Azacitidine FIVE Days/Monthly Schedule IN Symptomatic LOW-RISK (IPSS: 0-1) Myelodisplastic Patient.

Four Drugs Combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 65 Ys: Response and Follow-up of 84 Patients.

BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only